Sections

Overview

Practice Essentials

Prostate cancer represents the second most common cancer in men worldwide and the fifth most common cause of cancer death in men; in the United States, it is the most common cancer in men and the second most common cause of cancer deaths in men.^{[1, 2]}Acinar adenocarcinoma of the prostate comprises 90-95% of prostate cancers diagnosed.^[3]Ductal carcinoma and neuroendocrine carcinoma account for the majority of additional cases. The 2016 World Health Organization classification provides a comprehensive listing of prostate tumors, including acinar adenocarcinoma subtypes.^[4]In this article, the term prostate cancer refers to prostatic acinar adenocarcinoma.

The image below depicts the anatomic associations of the male urinary tract. The prostate lies between the bladder and the urogenital diaphragm. Owing to its anatomic location, the prostate may be palpable transrectally and accessed for biopsy via either the rectum or the perineum. For a more detailed description of prostate biopsy, see Workup/Prostate Biopsy.

Prostate cancer. This diagram depicts the relevant anatomy of the male pelvis and genitourinary tract.

View Media Gallery

For additional information please see Prostate Cancer: Diagnosis and Staging, a Critical Images slideshow, to help determine the best diagnostic approach for this potentially deadly disease and/or Advanced Prostate Cancer: Signs of Metastatic Disease, a Critical Images slideshow, for help identifying the signs of metastatic disease.

Signs and symptoms

Most patients presenting with prostate cancer do so with screen-detected cancer and are asymptomatic. Local symptoms associated with prostate cancer can include:

Lower urinary tract symptoms (LUTS)
Hematuria
Hematospermia
Erectile dysfunction
Urinary retention

However, those symptoms are generally not caused by prostate cancer. Physical examination alone cannot reliably differentiate benign prostatic disease from cancer.^[5]

Findings in patients with advanced disease may include the following:

Cancer cachexia
Bony tenderness
Lower-extremity lymphedema or deep venous thrombosis
Adenopathy
Overdistended bladder due to outlet obstruction
Neuropathy

See Presentation for more detail.

Screening

Multiple institutions and collaborative groups have addressed prostate cancer screening. The United States Preventive Services Task Force (USPSTF) recomended against prostate cancer screening in 2011-2012, but in 2018 reversed the recommendation to include screening after an informed discussion.

The evidence for and against screening, a summary of screening guidelines, and the observed impact of the USPSTF guidelines on prostate cancer incidence and mortality are presented in full detail in Workup/Prostate Cancer Screening.

Diagnosis

Elevated prostate-specific antigen (PSA) level

No PSA level guarantees the absence of prostate cancer.
The risk of disease increases as the PSA level increases, from about 8% with PSA levels of ≤1.0 ng/mL ^[6] to about 25% with PSA levels of 4-10 ng/mL and over 50% for levels over 10 ng/mL ^[6]

Abnormal digital rectal examination (DRE) findings

DRE is examiner-dependent, and serial examinations over time are best
Most patients diagnosed with prostate cancer have normal DRE results but abnormal PSA readings

Imaging

Multiparametric MRI is recommended as the initial diagnostic test for suspected prostate cancer. ^{[7, 8]}
Patients whose MRI results are highly suspicious for clinically significant prostate cancer should undergo prostate biopsy. ^[7]

Biopsy

Biopsy establishes the diagnosis.
Techniques include 12-core sampling guided by transrectal ultrasonography (TRUS), MRI-targeted biopsy, or both combined ^[9]
False-negative results often occur, so multiple biopsies may be needed before prostate cancer is detected.

Management

Localized prostate cancer

Standard treatments for clinically localized prostate cancer include the following:

Watchful waiting
Active surveillance
Radical prostatectomy
Radiation therapy

Emerging treatments with limited long-term data include targeted therapy and whole-gland ablation.

Non-localized or recurrent prostate cancer

Prostate cancer may recur in up to a third of men after definitive local therapy. This disease state is now subdivided into castrate-sensitive or castrate-resistant locally recurrent prostate cancer and castrate-sensitive or castrate-resistant metastatic prostate cancer. These disease states are rarely curable, but recent advances in the understanding of salvage radiation therapy, chemohormonal therapy, androgen blockade, and poly(ADP-ribose) polymerase (PARP) inhibition has greatly prolonged survival for these men. For full discussion of this rapidly developing field, see Metastatic and Advanced Prostate Cancer.

Background

Prostate cancer is the most common noncutaneous cancer in men in the United States. Although prostate cancer can be slow growing, thousands of men die of the disease each year. It is the second most common cause of cancer death in US males (see Epidemiology).

Marked variation in rates of prostate cancer among populations in different parts of the world suggests the involvement of genetic factors. Familial predisposition also occurs. Environmental factors, notably diet, are also important (see Etiology).

Currently, the majority of prostate cancers are identified in patients who are asymptomatic. Diagnosis in such cases is based on abnormalities in a screening prostate-specific antigen (PSA) level or findings on digital rectal examination (see Presentation and Workup).

Screening for prostate cancer is a controversial topic, in large part because of the conflicting findings from prospective, randomized studies (see Workup). Education about the risks and benefits is important to help men make informed decisions regarding screening and, in those diagnosed with prostate cancer, the various treatment options (see Treatment). (See the image below.)

If detected, prostate cancer is assigned a grade and stage followed by a risk group determination for consideration of therapy. Prostate cancer grading has traditionally been performed according to the Gleason Grading system. In this two-number system, the first number is assigned to the predominant focus of tumor and the second, to the second more predominant pattern (see the image below); each is graded on a scale of 1-5 and the sum of the two is the overall grade.^[10]Generally, the cut-off for prostate cancer starts with Gleason grade 3+3. However, the International Society of Urological Pathology (ISUP) has modified the Gleason system to a grade group system such that grade group 1 now encompasses Gleason 3+3 disease (see the Table below)

Prostate cancer. The standard approach for grading prostate cancer depends on a Gleason score, which is based on pathologic evaluation of a prostatectomy specimen and is commonly estimated from prostate biopsy tissue. Prostate cancer patterns are assigned a number from 1-5; the score is created by adding the most common pattern and the highest-grade patterns. Courtesy of Wikimedia Commons.

View Media Gallery

Table 1. Comparison of Gleason grade and modern Grade Groups. (Open Table in a new window)

Gleason Grade	Grade Groups
3+3	1
3+4	2
4+3	3
4+4, 3+5, 5+3	4
4+5, 5+4, 5+5	5

See also the following Medscape articles:

Anatomy

The prostate lies below the bladder and encompasses the prostatic urethra. It is surrounded by a capsule and is separated from the rectum by a layer of fascia termed the Denonvilliers aponeurosis. (See the image below.)

Prostate cancer. This diagram depicts the relevant anatomy of the male pelvis and genitourinary tract.

View Media Gallery

The inferior vesical artery, which is derived from the internal iliac artery, supplies blood to the base of the bladder and prostate. The capsular branches of the inferior vesical artery help to identify the pelvic plexus arising from the S2-4 and T10-12 nerve roots. The neurovascular bundle lies on either side of the prostate on the rectum. It is derived from the pelvic plexus and is important for erectile function. Venous drainage of the prostate occurs via the dorsal vein and Santorini's plexus, the latter of which might be responsible for hematogenous spread to the axial skeleton.

Pathophysiology

Prostate cancer develops when the rates of cell division exceed those of cell death, leading to uncontrolled tumor growth. Following the initial transformation event, further mutations of a multitude of genes, including the genes for p53 and retinoblastoma, can lead to tumor progression and metastasis. Most prostate cancers (90%) are adenocarcinomas.

Rarely, cancers may arise from the urothelial lining of the prostatic urethra. These are not prostatic adenocarcinomas but are treated as urothelial cancers.

Squamous cell carcinomas constitute less than 1% of all prostate carcinomas. In many cases, prostate carcinomas with squamous differentiation arise after radiation or hormone treatment.

Of prostate cancer cases, 70% arise in the peripheral zone, 15-20% arise in the central zone, and 10-15% arise in the transitional zone. Most prostate cancers are multifocal, with synchronous involvement of multiple zones of the prostate, which may be due to clonal and nonclonal tumors.

Local spread and metastasis

When these cancers are locally invasive, the transitional-zone tumors spread to the bladder neck, while the peripheral-zone tumors extend into the ejaculatory ducts and seminal vesicles. Penetration through the prostatic capsule and along the perineural or vascular spaces occurs relatively late.

The mechanism for distant metastasis is poorly understood. Cancer spreads to bone early, often without significant lymphadenopathy.

Natural history

Undiagnosed prostate cancer that does not affect survival has been frequently described. Incidental, unsuspected prostate cancers have been noted in 25-40% of prostate specimens when the bladder and prostate are removed for male bladder cancers.^[11]Latent prostate cancer has been described in numerous autopsy studies across several countries. Pooled analysis of several studies suggest that the prevalence of incidental prostate cancer at autopsy doubles for approximately every 14 years of life, with most of these cancer being of low Gleason grade.^[12]

Taken together, the prevalence of indolent prostate cancer combined with the lethality of some cases would suggest a spectrum of prostate cancer ranging from cancer that men die with and that which men die from. Indeed, a pooled analysis of several natural history evaluations would suggest that low-grade (Gleason 5-6) disease requires 10-15 years of lead time to develop into aggressive disease while higher-grade disease is associated with poor disease-specific mortality at 10 years if left untreated.^[13]It should be noted that Gleason 5 disease is no longer considered cancer.

With the advent of prostate cancer screening in the 1990’s, several epidemiologic evaluations have demonstrated a significant stage migration and improvements in prostate cancer mortality and thus the natural history, though with the caveat of overtreatment.^{[14, 15, 16]}This is discussed in greater detail in Workup/Prostate Cancer Screening.

Epidemiology and Etiology

Internationally, the incidence of prostate cancer varies by more than 50-fold, with the highest rates being in North America, Australia, and northern and central Europe and the lowest rates being in southeastern and south-central Asia and northern Africa.^{[1, 17]}

Occurrence and mortality in the United States

In the United States, prostate cancer is the most common noncutaneous cancer in men. An estimated one in six White men and one in five Black men will be diagnosed with prostate cancer in their lifetime, with the likelihood increasing with age. The American Cancer Society estimates that 288,300 new cases of prostate cancer will be diagnosed in 2023. Prostate cancer is rarely diagnosed in men younger than 40 years, and it is uncommon in men younger than 50 years.^[2]

Between 1989 and 1992, incidence rates of prostate cancer increased dramatically in the United States, probably because of earlier diagnoses in asymptomatic men as a result of the increased use of serum PSA testing. In addition, the incidence of organ-confined disease at diagnosis increased because of PSA testing and standard digital rectal examination. After 1992, incidence rates declined markedly, decreasing from over 230 per 100,000 population to 97 per 100,000 population in 2014.^[18]Subsequently, however, rates began rising; the incidence increased by 3% annually from 2014 through 2019.^[2]

Advanced disease accounts for a growing percentage of new prostate cancer cases. A review of almost 800,000 cases of prostate cancer diagnosed from 2004–2013 found that although the incidence of low-risk prostate cancer decreased from 2007-2013 to 37% less than that of 2004, the annual incidence of metastatic prostate cancer during those years increased to 72% more than that of 2004. The increase in metastatic prostate cancer was greatest (92%) in men aged 55–69 years.^[19]In 2015–2019, incidence rates for regional and distant prostate cancer increased by 4-6% per year.^[20]

Prostate cancer mortality rates began to decline in the early 1990s, in all racial and ethnic populations, decreasing from 39.3 per 100,000 persons in 1991 to 18.6 per 100,000 in 2020.^[18]However, in 2015-2019, the decline in death rates slowed for Black and Hispanic men and ceased for White and Asian American/Pacific Islander men.^[20]The American Cancer Society estimates that 34,700 men will die of prostate cancer in 2023.^[2]

Age-related demographics

Prostate cancer incidence increases as men age; as many as 60% of men over 65 years of age may be diagnosed with prostate cancer.^[17]Prostate cancer is most often diagnosed in men aged 65-74 years; median age at diagnosis is 66 years.^[18]

However, men as young as 17 years are experiencing an increasing incidence of prostate cancer in much of the world, including the United States, according to data from the Surveillance, Epidemiology, and End Results (SEER) program and the Institute for Health Metrics and Evaluation (IHME) Global Burden of Disease (GBD) database. These younger patients frequently present with more advanced cancer and have worse survival than middle-aged and older men. Worldwide, the incidence of prostate cancer has increased in men ages 15 to 40 years at a steady rate averaging 2% per year since 1990. In the United States, this age group was more than 6 times more likely than older men to have distant disease at diagnosis.^[21]

Racial demographics

In the United States, the incidence rate of prostate cancer is 70% higher in Black versus White men, and the prostate cancer mortality rate in Black men is 2-4 times higher than in every other racial and ethnic group.^[20]Worldwide, the incidence is highest in Blacks and Caribbean men of African descent, followed by Whites, Hispanics, and finally Asian men living in their native countries. Prostate cancer incidence is highest in countries with the highest socioeconomic index.^[22]

A cohort study of 7.8 million Veterans Affairs patients found that despite the equal access to care in this setting, incidence rates of localized and advanced prostate cancer were nearly twice as high in Black (African American) veterans as in White ones. Of the veterans with localized prostate cancer, Blacks were younger than Whites (median age, 63 vs 65 years) and had higher prostate-specific antigen levels (> 20 ng/mL) at the time of diagnosis. However, outcomes were similar in patients who received the same treatment, with lowered risk of metastasis.^[23]

Risk factors

Well-established risk factors for prostate include ethnicity, age, and country of residence. Additional risk factors include family history and genetic predisposition. For men with a family history (1 or more first-degree relatives) of breast cancer, the risk of prostate cancer diagnosis increases by 21%, and lethality increases by 34% compared with those without such history. Similarly, a family history of prostate cancer increases risk by 68% and lethality of disease by 72%, with a general trend favoring increases in risk according to earlier cancer onset in families.^[24]These associations have led to the identification of several germline mutations associated with hereditary prostate cancer, including HOXB13,BRCA1, BRCA2, DNA mismatch repair genes, ATM, CHEK2, PALB2, NBN, and RAD51D.^[25]

Discovery of these mutations has led to recommendations for the consideration of genetic testing for men with family histories that strongly suggest the presence of these mutations and men with metastatic castrate-resistant prostate cancer.^{[25, 26]}In men referred for genetic testing, about 20% will have a known genetic variation while only 63% will have a significant family history that would guide genetic testing decision making.^[27]BRCA1/2 and ATM mutations have been found in significantly higher rates for men with lethal prostate cancer.^[28]Overall, genetic testing remains a novel and developing area of prostate cancer research, but may ultimately inform screening, risk stratification, treatment aggressiveness, and (where currently applied) targeted systemic therapy for advanced disease.^[29]

An examination of cancer histories of 198 Lynch syndrome families, including probands and their first- through fourth-degree relatives, found that men with Lynch syndrome have a 2-fold higher risk of prostate cancer compared with the general population. Of the 4127 men involved in the study, 97 had prostate cancer. Median age at diagnosis was 65, with 11.5% diagnosed before age 50. The cumulative risk of prostate cancer for men with Lynch syndrome was 6.3% at age 60 and 30% at age 80, versus a population-wide risk of 2.6% and 17.8%, respectively.^[30]

Several additional risk factors are associated with either prostate cancer incidence but with lower levels of evidence, or conflicting evidence. Both increased body mass index (BMI) and additional components of the metabolic syndrome (eg, hyperinsulinemia, waist circumference) have been variably associated with both increased prostate cancer incidence and possibly increased recurrence after definitive therapy.^{[31, 32, 33, 34, 35]}

Increasing evidence suggests that the gut and genitourinary microbiome play a role in prostate cancer.^[36]Banerjee et al found that the microbiome signature (viral, bacterial, fungal, and parasitic elements) in prostate cancer samples differed from the microbiome signature in benign prostate hyperplasia controls. These authors also identified three distinct prostate cancer–specific microbiome signatures that correlated with different cancer grades, stages, and scores.^[37]

Hurst et al identified bacteria in urine collected after digital rectal examination and in secretions from prostatectomy samples and reported an association between the presence of bacteria and prostate cancer risk; the percentage of urine samples positive for bacteria rose from 17% in patients with low-risk prostate cancer to 100% of those with high-risk disease. In addition, the presence of five specific anaerobic genera, including three novel bacteria, was associated with aggressive prostate cancer risk.^[38]

Tobacco smoking, nutritional supplementation and/or deficiency, activity, and dietary components have also demonstrated variable association with prostate cancer incidence and/or mortality.^[39]Supplementation with selenium and vitamin E were prospectively evaluated for the prevention of the prostate cancer in the SELECT trial, which demonstrated an increase in prostate cancer cases for those given vitamin E only and no effect of selenium supplementation.^[40]The effect observed for vitamin E was not seen in other studies.^[41]The significant heterogeneity surrounding these risk factors suggests that further, nuanced evaluation is required before they can be classified as risk factors for prostate cancer or prostate cancer severity.

Prognosis

The most important and established indicators of prognosis for prostate carcinoma include the Gleason grade, the extent of tumor volume, and the presence of capsular penetration or margin positivity at the time of prostatectomy. High-grade prostate cancer, particularly the percentage of Gleason grades 4 and 5 that are present, is associated with adverse pathologic findings and disease progression. Conversely, low-grade prostate tumors are infrequently dangerous.

According to Surveillance, Epidemiology, and End Results (SEER) data from 2012 to 2018, 5-year relative survival for men with localized and regional prostate cancer is 100%, but is 32.3% for distant disease.^[18]In a review of 11,521 patients treated with radical prostatectomy at 4 academic centers from 1987 to 2005, Eggener et al reported an overall 15-year prostate cancer–specific mortality rate of 7%. High-grade cancer and seminal vesicle invasion were the prime determinants of prostate cancer–specific mortality.^[42]

Despite the steady decline in the incidence of newly diagnosed metastatic prostate cancer and microscopic lymph node metastasis, from 20% in the 1970s to 3.4% in the 1990s, the risk of extra-prostatic disease in patients with clinically localized disease remains high at approximately 30%. Depending on the PSA value, pathologic stage, and histologic grade of the tumor, approximately 30% of clinically localized prostate cancers are estimated to progress, despite initial treatment with intent to cure.

The Cancer of the Prostate Risk Assessment (CAPRA) score for predicting prognosis is calculated on the basis of the following:

PSA level
Gleason score
Percentage of biopsy cores positive for cancer
Clinical tumor stage
Age at diagnosis

In a study of 10,627 men with clinically localized prostate cancer who underwent primary radical prostatectomy, radiation therapy, androgen deprivation monotherapy, or watchful waiting/active surveillance, and had at least 6 months of follow-up after treatment, Cooperberg et al found that the CAPRA score was accurate for predicting metastases, cancer-specific mortality, and all-cause mortality.^[43]

In a multivariate analysis, biochemical recurrence and disease-specific mortality were much higher in men who were smokers at the time of diagnosis versus those who had never smoked. A higher number of pack-years was associated with significantly increased risk for prostate cancer mortality but not for biochemical recurrence. Men who had quit smoking 10 years prior to diagnosis—or who had quit more recently but smoked for < 20 pack-years—had prostate cancer–mortality risks much like those of men who had never smoked.^[44]

In a retrospective study at Johns Hopkins Medical Center in Baltimore, a greater connection between cigarette smoking and risk of prostate cancer recurrence was identified in men who had been treated with radical prostatectomy.^[45]Without prospective studies, however, these relationships remain hypothetical.

In an analysis of two large cohort studies of health professionals, researchers found a significantly increased risk for melanoma among men with prostate cancer. In 42,372 participants in the Health Professionals’ Follow-Up Study, a history of prostate cancer was independently associated with an increased risk for melanoma (hazard ratio, 1.83). This association was confirmed in an analysis of 18,603 participants in the Physicians’ Health Study (hazard ratio, 2.17).^[46]

Transitional cell carcinoma (TCC), prostatic stroma invasion, regardless of whether it represents primary or secondary involvement, is associated with poor prognosis (it is staged as pT4a bladder cancer). In contrast, prostatic involvement solely by cancer in situ (CIS) has no bearing on the staging of bladder cancer, although it may have implications for intravesical therapy.^{[47, 48, 49, 50, 51, 52]} The 5-year survival rate has ranged from 50% to 100% for patients with prostatic urothelium CIS alone and from 20% to 60% for patients with prostatic stroma invasion, independent of bladder tumor stage.^{[47, 48, 49, 50, 51, 53, 52]}

Molecular prognostic markers

Several prognostic tests have been shown to aid in determining the risk of harboring aggressive disease for patients with localized prostate cancers. This is an area of rapid change. Consensus regarding the applicability of different markers based on clinical scenarios remains elusive. Lamy and colleagues have published a detailed review of prognostic biomarkers used for management of localized prostate cancer.^[54]For discussion of markers utilized in the post-surgery or metastatic setting, see Metastatic and Advanced Prostate Cancer.

Patient Education

With the advent of PSA screening, and in the absence of level I studies comparing the various options, a greater number of men require education about prostate cancer and how it is diagnosed, staged, and treated. Such education allows patients to make informed decisions about screening and, in men diagnosed with prostate cancer, to select the most appropriate treatment. Up-to-date information is available through the National Cancer Institute and the American Cancer Society, as well as Prostate Videos.com.

For patient education information, see Prostate Cancer.

Clinical Presentation

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May. 71 (3):209-249. [QxMD MEDLINE Link]. [Full Text].
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023 Jan. 73 (1):17-48. [QxMD MEDLINE Link]. [Full Text].
Shah RB, Zhou M. Histologic Variants of Acinar Adenocarcinoma, Ductal Adenocarcinoma, Neuroendocrine Tumors, and Other Carcinomas. Prostate Biopsy Interpretation: An Illustrated Guide. 2nd ed. Switzerland: Springer Nature; 2019. 69-95.
Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. Eur Urol. 2016 Jul. 70 (1):106-119. [QxMD MEDLINE Link].
Merriel SWD, Funston G, Hamilton W. Prostate Cancer in Primary Care. Adv Ther. 2018 Sep. 35 (9):1285-1294. [QxMD MEDLINE Link].
Thompson IM Jr, Leach RJ, Ankerst DP. Focusing PSA Testing on Detection of High-Risk Prostate Cancers by Incorporating Patient Preferences Into Decision Making. JAMA. 2014 Aug 4. [QxMD MEDLINE Link].
[Guideline] National Comprehensive Cancer Network. Prostate Cancer Early Detection. National Comprehensive Cancer Network. Available at https://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf. Version 1.2023 — January 9, 2023; Accessed: January 20, 2023.
Barrett T, de Rooij M, Giganti F, Allen C, Barentsz JO, Padhani AR. Quality checkpoints in the MRI-directed prostate cancer diagnostic pathway. Nat Rev Urol. 2023 Jan. 20 (1):9-22. [QxMD MEDLINE Link].
Sidaway P. MRI, TRUS or both?. Nat Rev Clin Oncol. 2020 May. 17 (5):274. [QxMD MEDLINE Link]. [Full Text].
Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, et al. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. Eur Urol. 2016 Mar. 69 (3):428-35. [QxMD MEDLINE Link].
Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol. 2008 Feb. 15 (1):3866-71. [QxMD MEDLINE Link].
Sánchez-Chapado M, Olmedilla G, Cabeza M, Donat E, Ruiz A. Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: an autopsy study. Prostate. 2003 Feb 15. 54 (3):238-47. [QxMD MEDLINE Link].
Crawford ED. Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology. 2009 May. 73 (5 Suppl):S4-10. [QxMD MEDLINE Link].
Etzioni R, Tsodikov A, Mariotto A, Szabo A, Falcon S, Wegelin J, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control. 2008 Mar. 19 (2):175-81. [QxMD MEDLINE Link].
Howrey BT, Kuo YF, Lin YL, Goodwin JS. The impact of PSA screening on prostate cancer mortality and overdiagnosis of prostate cancer in the United States. J Gerontol A Biol Sci Med Sci. 2013 Jan. 68 (1):56-61. [QxMD MEDLINE Link].
van Leeuwen PJ, Connolly D, Gavin A, Roobol MJ, Black A, Bangma CH, et al. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit. Eur J Cancer. 2010 Jan. 46 (2):377-83. [QxMD MEDLINE Link].
Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019 Apr. 10 (2):63-89. [QxMD MEDLINE Link].
Cancer Stat Facts: Prostate Cancer. National Cancer Institute. Available at https://seer.cancer.gov/statfacts/html/prost.html. Accessed: January 17, 2023.
Weiner AB, Matulewicz RS, Eggener SE, Schaeffer EM. Increasing incidence of metastatic prostate cancer in the United States (2004-2013). Prostate Cancer Prostatic Dis. 2016 Jul 19. [QxMD MEDLINE Link]. [Full Text].
Schafer EJ, Jemal A, Wiese D, Sung H, Kratzer TB, Islami F, et al. Disparities and Trends in Genitourinary Cancer Incidence and Mortality in the USA. Eur Urol. 2022 Dec 21. [QxMD MEDLINE Link]. [Full Text].
Bleyer A, Spreafico F, Barr R. Prostate cancer in young men: An emerging young adult and older adolescent challenge. Cancer. 2019 Sep 25. [QxMD MEDLINE Link].
Pernar CH, Ebot EM, Wilson KM, Mucci LA. The Epidemiology of Prostate Cancer. Cold Spring Harb Perspect Med. 2018 Dec 3. 8 (12):[QxMD MEDLINE Link].
Yamoah K, Lee KM, Awasthi S, Alba PR, Perez C, Anglin-Foote TR, et al. Racial and Ethnic Disparities in Prostate Cancer Outcomes in the Veterans Affairs Health Care System. JAMA Netw Open. 2022 Jan 4. 5 (1):e2144027. [QxMD MEDLINE Link]. [Full Text].
Barber L, Gerke T, Markt SC, Peisch SF, Wilson KM, Ahearn T, et al. Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res. 2018 Dec 1. 24 (23):5910-5917. [QxMD MEDLINE Link].
Giri VN, Knudsen... Wender R, Gomella LG. Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. J Clin Oncol. 2018 Feb 1. 36 (4):414-424. [QxMD MEDLINE Link].
Giri VN, Hegarty SE, Hyatt C, O'Leary E, Garcia J, Knudsen KE, et al. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing. Prostate. 2019 Mar. 79 (4):333-339. [QxMD MEDLINE Link].
Nicolosi P, Ledet E, Yang S, Michalski S, Freschi B, O'Leary E, et al. Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines. JAMA Oncol. 2019 Apr 1. 5 (4):523-528. [QxMD MEDLINE Link].
Na R, Zheng SL, ... Xu J, Isaacs WB. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. Eur Urol. 2017 May. 71 (5):740-747. [QxMD MEDLINE Link].
Marshall CH, Sokolova AO, McNatty AL, Cheng HH, Eisenberger MA, Bryce AH, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol. 2019 Oct. 76 (4):452-458. [QxMD MEDLINE Link].
Raymond VM, Mukherjee B, Wang F, Huang SC, Stoffel EM, Kastrinos F, et al. Elevated Risk of Prostate Cancer Among Men With Lynch Syndrome. J Clin Oncol. 2013 Mar 25. [QxMD MEDLINE Link].
Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2011 Apr. 4 (4):486-501. [QxMD MEDLINE Link].
Ma J, Li H, Giovannucci E, Mucci L, Qiu W, Nguyen PL, et al. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol. 2008 Nov. 9 (11):1039-47. [QxMD MEDLINE Link].
Stevens VL, Jacobs EJ, Sun J, Gapstur SM. No association of plasma levels of adiponectin and c-peptide with risk of aggressive prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev. 2014 May. 23 (5):890-2. [QxMD MEDLINE Link].
Pischon T, Boeing H, Weikert S, Allen N, Key T, ...Slimani N, et al. Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev. 2008 Nov. 17 (11):3252-61. [QxMD MEDLINE Link].
Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Height, body weight, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 1997 Aug. 6 (8):557-63. [QxMD MEDLINE Link].
Wheeler KM, Liss MA. The Microbiome and Prostate Cancer Risk. Curr Urol Rep. 2019 Sep 7. 20 (10):66. [QxMD MEDLINE Link].
Banerjee S, Alwine JC, Wei Z, Tian T, Shih N, Sperling C, et al. Microbiome signatures in prostate cancer. Carcinogenesis. 2019 Jul 6. 40 (6):749-764. [QxMD MEDLINE Link].
Hurst R, Meader E, Gihawi A, et al. Microbiomes of Urine and the Prostate Are Linked to Human Prostate Cancer Risk Groups. Eur Urol Oncol. 2022 Apr 18. [QxMD MEDLINE Link]. [Full Text].
Mucci LA, Wilson KM, Giovannucci EL. Epidemiology of Prostate Cancer. Loda M, Mucci LA, Mittelstadt ML, Van Hemelrijck M, Cotter MB. Pathology and Epidemiology of Cancer. Springer International Publishing; 2017. 107-125.
Klein EA, Thompson IM Jr, Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011 Oct 12. 306 (14):1549-56. [QxMD MEDLINE Link].
Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA. 2009 Jan 7. 301 (1):52-62. [QxMD MEDLINE Link].
Eggener SE, Scardino PT, Walsh PC, Han M, et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol. 2011 Mar. 185(3):869-75. [QxMD MEDLINE Link].
Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst. 2009 Jun 16. 101(12):878-87. [QxMD MEDLINE Link]. [Full Text].
Kenfield SA, Stampfer MJ, Chan JM, Giovannucci E. Smoking and prostate cancer survival and recurrence. JAMA. 2011 Jun 22. 305(24):2548-55. [QxMD MEDLINE Link]. [Full Text].
Joshu CE, Mondul AM, Meinhold CL, Humphreys EB, Han M, Walsh PC, et al. Cigarette smoking and prostate cancer recurrence after prostatectomy. J Natl Cancer Inst. 2011 May 18. 103(10):835-8. [QxMD MEDLINE Link]. [Full Text].
Li WQ, Qureshi AA, Ma J, Goldstein AM, Giovannucci EL, Stampfer MJ, et al. Personal History of Prostate Cancer and Increased Risk of Incident Melanoma in the United States. J Clin Oncol. 2013 Nov 4. [QxMD MEDLINE Link].
Esrig D, Freeman JA, Elmajian DA, et al. Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion. J Urol. 1996 Sep. 156 (3):1071-6. [QxMD MEDLINE Link].
Reese JH, Freiha FS, Gelb AB, Lum BL, Torti FM. Transitional cell carcinoma of the prostate in patients undergoing radical cystoprostatectomy. J Urol. 1992 Jan. 147 (1):92-5. [QxMD MEDLINE Link].
Revelo MP, Cookson MS, Chang SS, Shook MF, Smith JA Jr, Shappell SB. Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery. J Urol. 2004 Feb. 171 (2 Pt 1):646-51. [QxMD MEDLINE Link].
Njinou Ngninkeu B, Lorge F, Moulin P, Jamart J, Van Cangh PJ. Transitional cell carcinoma involving the prostate: a clinicopathological retrospective study of 76 cases. J Urol. 2003 Jan. 169 (1):149-52. [QxMD MEDLINE Link].
Shen SS, Lerner SP, Muezzinoglu B, Truong LD, Amiel G, Wheeler TM. Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol. 2006 Jun. 37 (6):726-34. [QxMD MEDLINE Link].
Cheville JC, Dundore PA, Bostwick DG, et al. Transitional cell carcinoma of the prostate: clinicopathologic study of 50 cases. Cancer. 1998 Feb 15. 82 (4):703-7. [QxMD MEDLINE Link].
Pettus JA, Al-Ahmadie H, Barocas DA, et al. Risk assessment of prostatic pathology in patients undergoing radical cystoprostatectomy. Eur Urol. 2008 Feb. 53 (2):370-5. [QxMD MEDLINE Link].
Lamy PJ, Allory Y, Gauchez AS, Asselain B, Beuzeboc P, de Cremoux P, et al. Prognostic Biomarkers Used for Localised Prostate Cancer Management: A Systematic Review. Eur Urol Focus. 2018 Dec. 4 (6):790-803. [QxMD MEDLINE Link].
Lerner SP, Shen S. Pathologic assessment and clinical significance of prostatic involvement by transitional cell carcinoma and prostate cancer. Urol Oncol. 2008 Sep-Oct. 26 (5):481-5. [QxMD MEDLINE Link].
Wood DP Jr, Montie JE, Pontes JE, VanderBrug Medendorp S, Levin HS. Transitional cell carcinoma of the prostate in cystoprostatectomy specimens removed for bladder cancer. J Urol. 1989 Feb. 141 (2):346-9. [QxMD MEDLINE Link].
Komyakov BK, Sergeev AV, Fadeev VA, et al. [Concomitant oncopathological changes in the prostate of urinary bladder cancer patients undergoing radical cystoprostateectomy] [Russian]. Urologiia. 2017 Sep. 42-5. [QxMD MEDLINE Link].
[Guideline] Prostate Cancer. National Comprehensive Cancer Network. Available at http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Version 2.2021 — February 17, 2021; Accessed: March 10, 2021.
Naji L, Randhawa H, Sohani Z, Dennis B, Lautenbach D, Kavanagh O, et al. Digital Rectal Examination for Prostate Cancer Screening in Primary Care: A Systematic Review and Meta-Analysis. Ann Fam Med. 2018 Mar. 16 (2):149-154. [QxMD MEDLINE Link]. [Full Text].
Hu JC, Nguyen P, Mao J, Halpern J, Shoag J, Wright JD, et al. Increase in Prostate Cancer Distant Metastases at Diagnosis in the United States. JAMA Oncol. 2017 May 1. 3 (5):705-707. [QxMD MEDLINE Link].
Pinsky PF, Prorok PC, Yu K, Kramer BS, Black A, Gohagan JK, et al. Extended mortality results for prostate cancer screening in the PLCO trial with median follow-up of 15 years. Cancer. 2017 Feb 15. 123 (4):592-599. [QxMD MEDLINE Link].
Schröder FH, Hugosson J, Roobol MJ, ....Auvinen A, ERSPC Investigators. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet. 2014 Dec 6. 384 (9959):2027-35. [QxMD MEDLINE Link].
Arnsrud Godtman R, Holmberg E, Lilja H, Stranne J, Hugosson J. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. Eur Urol. 2015 Sep. 68 (3):354-60. [QxMD MEDLINE Link].
Roobol MJ, Kerkhof M, Schröder FH, Cuzick J, ...Hugosson J, Auvinen A. Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol. 2009 Oct. 56 (4):584-91. [QxMD MEDLINE Link].
Tabár L, Vitak B, Chen TH, Yen AM, Cohen A, Tot T, et al. Swedish two-county trial: impact of mammographic screening on breast cancer mortality during 3 decades. Radiology. 2011 Sep. 260 (3):658-63. [QxMD MEDLINE Link].
Siu AL, U.S. Preventive Services Task Force. Screening for Breast Cancer: U.S. Preventive Services Task Force Recommendation Statement. Ann Intern Med. 2016 Feb 16. 164 (4):279-96. [QxMD MEDLINE Link].
Carlsson S, Vickers AJ, Roobol M, Eastham J, Scardino P, Lilja H, et al. Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. J Clin Oncol. 2012 Jul 20. 30 (21):2581-4. [QxMD MEDLINE Link].
Butler SS, Muralidhar V, Zhao SG, Sanford NN, Franco I, Fullerton ZH, et al. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. Cancer. 2020 Feb 15. 126 (4):717-724. [QxMD MEDLINE Link].
Wilt TJ, Vo TN, Langsetmo L, Dahm P, Wheeler T, Aronson WJ, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol. 2020 Jun. 77 (6):713-724. [QxMD MEDLINE Link].
US Preventive Services Task Force., Grossman DC, Curry SJ, Owens DK, Bibbins-Domingo K, Caughey AB, et al. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2018 May 8. 319 (18):1901-1913. [QxMD MEDLINE Link].
Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, et al. Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2019 May. 69 (3):184-210. [QxMD MEDLINE Link].
[Guideline] Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2017 Apr. 71 (4):618-629. [QxMD MEDLINE Link].
Daskivich TJ, Fan KH, Koyama T, Albertsen PC, Goodman M, Hamilton AS, et al. Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med. 2013 May 21. 158 (10):709-17. [QxMD MEDLINE Link].
American Cancer Society Recommendations for Prostate Cancer Early Detection. American Cancer Society. Available at http://www.cancer.org/Cancer/ProstateCancer/MoreInformation/ProstateCancerEarlyDetection/prostate-cancer-early-detection-acs-recommendations. April 23, 2021; Accessed: January 20, 2023.
Bul M, van Leeuwen PJ, Zhu X, Schröder FH, Roobol MJ. Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam. Eur Urol. 2011 Apr. 59(4):498-505. [QxMD MEDLINE Link].
Bul M, van Leeuwen PJ, Zhu X, Schröder FH, Roobol MJ. Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam. Eur Urol. 2011 Apr. 59(4):498-505. [QxMD MEDLINE Link].
Shao YH, Albertsen PC, Roberts CB, Lin Y, Mehta AR, Stein MN, et al. Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml. Arch Intern Med. 2010 Jul 26. 170(14):1256-61. [QxMD MEDLINE Link].
Preston MA, Batista JL, Wilson KM, Carlsson SV, Gerke T, Sjoberg DD, et al. Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. J Clin Oncol. 2016 Jun 13. [QxMD MEDLINE Link].
Vickers AJ, Till C, Tangen CM, Lilja H, Thompson IM. An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. J Natl Cancer Inst. 2011 Mar 16. 103(6):462-9. [QxMD MEDLINE Link]. [Full Text].
Mohammed W, Davis NF, Elamin S, Ahern P, Brady CM, Sweeney P. Six-core versus twelve-core prostate biopsy: a retrospective study comparing accuracy, oncological outcomes and safety. Ir J Med Sci. 2016 Feb. 185 (1):219-23. [QxMD MEDLINE Link].
Bjurlin MA, Carter HB, Schellhammer P, Cookson MS, Gomella LG, Troyer D, et al. Optimization of initial prostate biopsy in clinical practice: sampling, labeling and specimen processing. J Urol. 2013 Jun. 189 (6):2039-46. [QxMD MEDLINE Link].
Borghesi M, Ahmed H, Nam R, Schaeffer E, Schiavina R, Taneja S, et al. Complications After Systematic, Random, and Image-guided Prostate Biopsy. Eur Urol. 2017 Mar. 71 (3):353-365. [QxMD MEDLINE Link].
Stefanova V, Buckley R, Flax S, Spevack L, Hajek D, Tunis A, et al. Transperineal Prostate Biopsies Using Local Anesthesia: Experience with 1,287 Patients. Prostate Cancer Detection Rate, Complications and Patient Tolerability. J Urol. 2019 Jun. 201 (6):1121-1126. [QxMD MEDLINE Link].
Pepe P, Aragona F. Morbidity after transperineal prostate biopsy in 3000 patients undergoing 12 vs 18 vs more than 24 needle cores. Urology. 2013 Jun. 81 (6):1142-6. [QxMD MEDLINE Link].
Xue J, Qin Z, Cai H, Zhang C, Li X, Xu W, et al. Comparison between transrectal and transperineal prostate biopsy for detection of prostate cancer: a meta-analysis and trial sequential analysis. Oncotarget. 2017 Apr 4. 8 (14):23322-23336. [QxMD MEDLINE Link].
Weinreb JC, Barentsz JO, Choyke PL, Cornud F, Haider MA, Macura KJ, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, Version 2. Eur Urol. 2016 Jan. 69 (1):16-40. [QxMD MEDLINE Link].
Rosenkrantz AB, Verma S, Choyke P, Eberhardt SC, Eggener SE, Gaitonde K, et al. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by AUA and SAR. J Urol. 2016 Dec. 196 (6):1613-1618. [QxMD MEDLINE Link].
van der Leest M, Cornel E, Israël B,...Hulsbergen-van de Kaa C, Barentsz JO. Head-to-head Comparison of Transrectal Ultrasound-guided Prostate Biopsy Versus Multiparametric Prostate Resonance Imaging with Subsequent Magnetic Resonance-guided Biopsy in Biopsy-naïve Men with Elevated Prostate-specific Antigen: A Large Prospective Multicenter Clinical Study. Eur Urol. 2019 Apr. 75 (4):570-578. [QxMD MEDLINE Link].
Kasivisvanathan V, Rannikko AS, .... Moore CM, PRECISION Study Group Collaborators. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018 May 10. 378 (19):1767-1777. [QxMD MEDLINE Link].
Hamoen EHJ, Hoeks CMA, Somford DM, van Oort IM, Vergunst H, Oddens JR, et al. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up. Eur Urol Focus. 2019 May. 5 (3):407-415. [QxMD MEDLINE Link].
Tran GN, Leapman MS, Nguyen HG, Cowan JE, Shinohara K, Westphalen AC, et al. Magnetic Resonance Imaging-Ultrasound Fusion Biopsy During Prostate Cancer Active Surveillance. Eur Urol. 2017 Aug. 72 (2):275-281. [QxMD MEDLINE Link].
Nassiri N, Margolis DJ, Natarajan S, Sharma DS, Huang J, Dorey FJ, et al. Targeted Biopsy to Detect Gleason Score Upgrading during Active Surveillance for Men with Low versus Intermediate Risk Prostate Cancer. J Urol. 2017 Mar. 197 (3 Pt 1):632-639. [QxMD MEDLINE Link].
Aharony S, Baniel J, Yossepowitch O. Clinically unconfirmed positive urinary cytology: diagnostic implications and oncological outcomes. BJU Int. 2011 Oct. 108 (8 pt 2):E179-83. [QxMD MEDLINE Link].
Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, et al. A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. Eur Urol. 2016 Mar. 69 (3):428-35. [QxMD MEDLINE Link].
Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA, et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016 Feb. 40 (2):244-52. [QxMD MEDLINE Link].
Buyyounouski MK, Choyke PL, McKenney JK, Sartor O, Sandler HM, Amin MB, et al. Prostate cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017 May 6. 67 (3):245-253. [QxMD MEDLINE Link]. [Full Text].
Poyet C, Nieboer D, Bhindi B, Kulkarni GS, Wiederkehr C, Wettstein MS, et al. Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort. BJU Int. 2016 Mar. 117 (3):401-8. [QxMD MEDLINE Link].
Rowe SP, Gorin MA, Allaf ME, Pienta KJ, Tran PT, Pomper MG, et al. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer Prostatic Dis. 2016 Sep. 19 (3):223-30. [QxMD MEDLINE Link].
Eifler JB, Feng Z, Lin BM, Partin MT, Humphreys EB, Han M, et al. An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. BJU Int. 2013 Jan. 111(1):22-9. [QxMD MEDLINE Link].
Cooperberg MR, Broering JM, Carroll PR. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst. 2009 Jun 16. 101(12):878-87. [QxMD MEDLINE Link]. [Full Text].
Crawford ED, Blumenstein BA. Proposed substages for metastatic prostate cancer. Urology. 1997 Dec. 50(6):1027-8. [QxMD MEDLINE Link].
Olsen JR, Azeem W, Hellem MR, et al. Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes. BMC Cancer. 2016 Jul 4. 16:377. [QxMD MEDLINE Link]. [Full Text].
Varinot J, Cussenot O, Roupret M, et al. HOXB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin. Virchows Arch. 2013 Dec. 463 (6):803-9. [QxMD MEDLINE Link].
Kim HJ, Yoo JH. Cytokeratin 20/p53 dual immunocytochemistry for improving the diagnostic accuracy of urine liquid-based cytology in the detection of urothelial neoplasm: A retrospective study. Cytojournal. 2017. 14:27. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Eastham JA, Auffenberg GB, Barocas DA, Chou R, Crispino T, Davis JW, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up. J Urol. 2022 Jul. 208 (1):19-25. [QxMD MEDLINE Link]. [Full Text].
PDQ Adult Treatment Editorial Board. Prostate Cancer Treatment (PDQ®). National Cancer Institute. Available at http://www.cancer.gov/cancertopics/pdq/treatment/prostate/HealthProfessional/page4. December 27, 2021; Accessed: January 21, 2022.
EAU Virtual: EUPROMS Study Investigates Effect of Prostate Cancer Treatment on Quality of Life. ASCO Post. Available at https://www.ascopost.com/news/july-2020/euproms-study-investigates-effect-of-prostate-cancer-treatment-on-quality-of-life. July 31, 2020; Accessed: January 21, 2022.
Wilt TJ, Vo TN, Langsetmo L, Dahm P, Wheeler T, Aronson WJ, et al. Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol. 2020 Jun. 77 (6):713-724. [QxMD MEDLINE Link].
Froehner M, Koch R, Hübler M, Renner T, Borkowetz A, Zastrow S, et al. Only <10% of Patients Selected for Radical Prostatectomy Reach the Competing Mortality Rate of the Prostate Cancer Intervention Versus Observation Trial (PIVOT). Eur Urol Focus. 2019 May. 5 (3):361-364. [QxMD MEDLINE Link].
Iversen P, Madsen PO, Corle DK. Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. Scand J Urol Nephrol Suppl. 1995. 172:65-72. [QxMD MEDLINE Link].
Bill-Axelson A, Holmberg L, Garmo H, Taari K, Busch C, Nordling S, et al. Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up. N Engl J Med. 2018 Dec 13. 379 (24):2319-2329. [QxMD MEDLINE Link].
Paudel R, Madan R, Qi J, Ferrante S, Cher ML, Lane BR, et al. The Use and Short-term Outcomes of Active Surveillance in Men With National Comprehensive Cancer Network Favorable Intermediate-risk Prostate Cancer: The Initial Michigan Urological Surgery Improvement Collaborative Experience. J Urol. 2023 Jan. 209 (1):170-179. [QxMD MEDLINE Link].
Bruinsma SM, Bangma CH, Carroll PR, Leapman MS, Rannikko A, Petrides N, et al. Active surveillance for prostate cancer: a narrative review of clinical guidelines. Nat Rev Urol. 2016 Mar. 13 (3):151-67. [QxMD MEDLINE Link].
Litwin MS, Tan HJ. The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA. 2017 Jun 27. 317 (24):2532-2542. [QxMD MEDLINE Link].
Hamdy FC, Donovan JL, Lane JA, Mason M, ...Neal DE, ProtecT Study Group. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med. 2016 Oct 13. 375 (15):1415-1424. [QxMD MEDLINE Link].
Chen RC. Radiation therapy for prostate cancer: An evolving treatment modality. Urol Oncol. 2019 Sep. 37 (9):579-581. [QxMD MEDLINE Link].
Brooks NA, Boland RS, Strigenz ME, Mott SL, Brown JA. Nongenitourinary complications associated with robot-assisted laparoscopic and radical retropubic prostatectomy: A single institution assessment of 1,100 patients over 11 years. Urol Oncol. 2018 Nov. 36 (11):501.e9-501.e13. [QxMD MEDLINE Link].
Spector BL, Brooks NA, Strigenz ME, Brown JA. Bladder Neck Contracture Following Radical Retropubic versus Robotic-Assisted Laparoscopic Prostatectomy. Curr Urol. 2017 Aug. 10 (3):145-149. [QxMD MEDLINE Link].
Menon M, Dalela D, Jamil M, Diaz M, Tallman C, Abdollah F, et al. Functional Recovery, Oncologic Outcomes and Postoperative Complications after Robot-Assisted Radical Prostatectomy: An Evidence-Based Analysis Comparing the Retzius Sparing and Standard Approaches. J Urol. 2018 May. 199 (5):1210-1217. [QxMD MEDLINE Link].
Geinitz H, Thamm R, Keller M, Astner ST, Heinrich C, et al. Longitudinal study of intestinal symptoms and fecal continence in patients with conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Apr 1. 79(5):1373-80. [QxMD MEDLINE Link].
Margel D, Baniel J, Wasserberg N, Bar-Chana M, Yossepowitch O. Radiation therapy for prostate cancer increases the risk of subsequent rectal cancer. Ann Surg. 2011 Dec. 254(6):947-50. [QxMD MEDLINE Link].
Nihei K, Ogino T, Onozawa M, Murayama S, Fuji H, Murakami M, et al. Multi-institutional Phase II study of proton beam therapy for organ-confined prostate cancer focusing on the incidence of late rectal toxicities. Int J Radiat Oncol Biol Phys. 2011 Oct 1. 81(2):390-6. [QxMD MEDLINE Link].
Wallis CJ, Mahar AL, Choo R, Herschorn S, Kodama RT, Shah PS, et al. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ. 2016 Mar 2. 352:i851. [QxMD MEDLINE Link]. [Full Text].
Walsh PC. Anatomic radical prostatectomy: evolution of the surgical technique. J Urol. 1998 Dec. 160 (6 Pt 2):2418-24. [QxMD MEDLINE Link].
Sriprasad S, Feneley MR, Thompson PM. History of prostate cancer treatment. Surg Oncol. 2009 Sep. 18 (3):185-91. [QxMD MEDLINE Link].
van Poppel H, Everaerts W, Tosco L, Joniau S. Open and robotic radical prostatectomy. Asian J Urol. 2019 Apr. 6 (2):125-128. [QxMD MEDLINE Link].
Lowrance WT, Eastham JA, Savage C, Maschino AC, Laudone VP, Dechet CB, et al. Contemporary open and robotic radical prostatectomy practice patterns among urologists in the United States. J Urol. 2012 Jun. 187 (6):2087-92. [QxMD MEDLINE Link].
Oberlin DT, Flum AS, Lai JD, Meeks JJ. The effect of minimally invasive prostatectomy on practice patterns of American urologists. Urol Oncol. 2016 Jun. 34 (6):255.e1-5. [QxMD MEDLINE Link].
McAlpine K, Forster AJ, Breau RH, McIsaac D, Tufts J, Mallick R, et al. Robotic surgery improves transfusion rate and perioperative outcomes using a broad implementation process and multiple surgeon learning curves. Can Urol Assoc J. 2019 Jun. 13 (6):184-189. [QxMD MEDLINE Link].
Preisser F, Busto Martin L, Pompe RS, Heinze A, Haese A, Graefen M, et al. Effect of bladder neck sparing at robot-assisted laparoscopic prostatectomy on postoperative continence rates and biochemical recurrence. Urol Oncol. 2020 Jan. 38 (1):1.e11-1.e16. [QxMD MEDLINE Link].
Sooriakumaran P, Pini G, Nyberg T, Derogar M, Carlsson S, Stranne J, et al. Erectile Function and Oncologic Outcomes Following Open Retropubic and Robot-assisted Radical Prostatectomy: Results from the LAParoscopic Prostatectomy Robot Open Trial. Eur Urol. 2018 Apr. 73 (4):618-627. [QxMD MEDLINE Link].
Basiri A, de la Rosette JJ, Tabatabaei S, Woo HH, Laguna MP, Shemshaki H. Comparison of retropubic, laparoscopic and robotic radical prostatectomy: who is the winner?. World J Urol. 2018 Apr. 36 (4):609-621. [QxMD MEDLINE Link].
[Guideline] Rosenthal SA, Bittner NH, Beyer DC, Demanes DJ, et al. American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) practice guideline for the transperineal permanent brachytherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Feb 1. 79(2):335-41. [QxMD MEDLINE Link].
D'Amico AV, Chen MH, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008 Jan 23. 299(3):289-95. [QxMD MEDLINE Link].
Jones CU, Hunt D, McGowan DG, Amin MB et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med. 2011 Jul 14. 365(2):107-18. [QxMD MEDLINE Link].
Pisansky TM, Hunt D, Gomella LG, Amin MB, Balogh AG, Chinn DM, et al. Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910. J Clin Oncol. 2015 Feb 1. 33 (4):332-9. [QxMD MEDLINE Link]. [Full Text].
Therapies for Clinically Localized Prostate Cancer: Update of a 2008 Systematic Review. AHRQ. Available at https://effectivehealthcare.ahrq.gov/topics/prostate-cancer-therapies-update/research. December 16, 2014; Accessed: September 14, 2020.
Bolla M, et al; European Organisation for Research and Treatment of Cancer, Radiation Oncology and Genito-Urinary Groups. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet,. 2012 Dec 8. 380 (9858):2018-27. [QxMD MEDLINE Link].
Thompson IM Jr, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA. 2006 Nov 15. 296 (19):2329-35. [QxMD MEDLINE Link].
Wiegel T, Bartkowiak D, Bottke D, Bronner C, Steiner U, Siegmann A, et al. Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02/AUO AP 09/95 trial. Eur Urol. 2014 Aug. 66 (2):243-50. [QxMD MEDLINE Link].
Hackman G, Taari K, Tammela TL, ...Hemminki A, FinnProstate Group. Randomised Trial of Adjuvant Radiotherapy Following Radical Prostatectomy Versus Radical Prostatectomy Alone in Prostate Cancer Patients with Positive Margins or Extracapsular Extension. Eur Urol. 2019 Nov. 76 (5):586-595. [QxMD MEDLINE Link].
Thompson IM, Valicenti RK, Albertsen P, Davis BJ, Goldenberg SL, Hahn C, et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol. 2013 Aug. 190 (2):441-9. [QxMD MEDLINE Link].
Labbate CV, Klotz L, Morrow M, Cooperberg M, Esserman L, Eggener SE. Focal Therapy for Prostate Cancer: Evolutionary Parallels to Breast Cancer Treatment. J Urol. 2023 Jan. 209 (1):49-57. [QxMD MEDLINE Link]. [Full Text].
Shah TT, Peters M, Arya M, Ahmed HU. Reply to Zhipeng Mai's Letter to the Editor re: Taimur T. Shah, Max Peters, David Eldred-Evans, et al. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. Eur Urol 2019;76:98-105. Eur Urol. 2019 Sep. 76 (3):e63-e64. [QxMD MEDLINE Link].
Noweski A, Roosen A, Lebdai S, Barret E, Emberton M, Benzaghou F, et al. Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials). Eur Urol Focus. 2019 Nov. 5 (6):1022-1028. [QxMD MEDLINE Link].
Wang L, Yang H, Li B. Photodynamic therapy for prostate cancer: a systematic review and meta-analysis. Prostate Int. 2019 Sep. 7 (3):83-90. [QxMD MEDLINE Link].
Kimura M, Mouraviev V, Tsivian M, Mayes JM, Satoh T, Polascik TJ. Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. BJU Int. 2010 Jan. 105 (2):191-201. [QxMD MEDLINE Link].
Bahn D, de Castro Abreu AL, Gill IS, Hung AJ, Silverman P, Gross ME, et al. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol. 2012 Jul. 62(1):55-63. [QxMD MEDLINE Link].
Gill IS, Azzouzi AR, Emberton M, Coleman JA, Coeytaux E, Scherz A, et al. Randomized Trial of Partial Gland Ablation with Vascular Targeted Phototherapy versus Active Surveillance for Low Risk Prostate Cancer: Extended Followup and Analyses of Effectiveness. J Urol. 2018 Oct. 200 (4):786-793. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Lowrance W, Breau R, Chou R, et al. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline. American Urological Association. Available at https://www.auanet.org/guidelines/advanced-prostate-cancer. June 25, 2020; Accessed: July 22, 2020.
Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016 Apr 20. 34 (12):1402-18. [QxMD MEDLINE Link].
Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, Walsh PC, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA. 2005 Jul 27. 294(4):433-9. [QxMD MEDLINE Link].
Fu AZ, Tsai HT, Haque R, Yood MU, Cassidy-Bushrow AE, Van Den Eeden SK, et al. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer. J Urol. 2017 Jun. 197 (6):1448-1454. [QxMD MEDLINE Link].
Garcia-Albeniz X, Chan JM, Paciorek A, Logan RW, Kenfield SA, Cooperberg MR, et al. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study. Eur J Cancer. 2015 May. 51 (7):817-24. [QxMD MEDLINE Link].
Crook JM, O'Callaghan CJ, Duncan G, Dearnaley DP, et al. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012 Sep 6. 367(10):895-903. [QxMD MEDLINE Link]. [Full Text].
Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet. 2000 Apr 29. 355(9214):1491-8. [QxMD MEDLINE Link].
Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-7.
Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr. 1988. 165-70. [QxMD MEDLINE Link].
Crawford ED, Blumenstein BA, Goodman PJ, et al. Leuprolide with and without flutamide in advanced prostate cancer. Cancer. 1990 Sep 1. 66(5 Suppl):1039-44. [QxMD MEDLINE Link].
Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol. 1997 Feb. 79(2):235-46. [QxMD MEDLINE Link].
Calais da Silva FE, Bono AV, Whelan P, Brausi M, et al. Intermittent androgen deprivation for locally advanced and metastatic prostate cancer: results from a randomised phase 3 study of the South European Uroncological Group. Eur Urol. 2009 Jun. 55(6):1269-77. [QxMD MEDLINE Link].
Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med. 2013 Apr 4. 368(14):1314-25. [QxMD MEDLINE Link].
Fizazi K, Tran N, Fein L, et al; LATITUDE Investigators. Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer. N Engl J Med. 2017 Jul 27. 377 (4):352-360. [QxMD MEDLINE Link]. [Full Text].
James ND, de Bono JS, Spears MR, et al, for the STAMPEDE investigators. Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. N Engl J Med. June 3, 2017. [Full Text].
Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019 Jul 11. 381 (2):121-131. [QxMD MEDLINE Link].
Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol. 2019 Nov 10. 37 (32):2974-2986. [QxMD MEDLINE Link].
Sweeney CJ, Chen YH, Carducci M, Liu G, Jarrard DF, Eisenberger M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med. 2015 Aug 5. 42 (9):863-6. [QxMD MEDLINE Link]. [Full Text].
James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016 Mar 19. 387 (10024):1163-77. [QxMD MEDLINE Link].
Shore ND, Saad F, Cookson MS, et al, and the, HERO Study Investigators. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med. 2020 Jun 4. 382 (23):2187-2196. [QxMD MEDLINE Link].
Smith MR, Saad F, Coleman R, Shore N, Fizazi K, Tombal B, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012 Jan 7. 379 (9810):39-46. [QxMD MEDLINE Link].
Bryce AH, Alumkal JJ, Armstrong A, Higano CS, Iversen P, Sternberg CN, et al. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer Prostatic Dis. 2017 Jun. 20 (2):221-227. [QxMD MEDLINE Link].
Qi WX, Shen Z, Yao Y. Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials. J Cancer Res Clin Oncol. 2011 Dec. 137(12):1785-90. [QxMD MEDLINE Link].
Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004 Oct 7. 351 (15):1513-20. [QxMD MEDLINE Link].
Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004 Oct 7. 351(15):1502-12. [QxMD MEDLINE Link].
Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol. 2008 Jan 10. 26(2):242-5. [QxMD MEDLINE Link].
Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, et al. Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1. J Clin Oncol. 2016 Jul 11. [QxMD MEDLINE Link].
Sartor O, de Bono J, Chi KN, and the, VISION Investigators. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021 Sep 16. 385 (12):1091-1103. [QxMD MEDLINE Link]. [Full Text].
Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010 Jul 29. 363 (5):411-22. [QxMD MEDLINE Link]. [Full Text].
de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011 May 26. 364(21):1995-2005. [QxMD MEDLINE Link]. [Full Text].
Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012 Oct. 13(10):983-92. [QxMD MEDLINE Link].
US Food and Drug Administration. FDA expands Zytiga’s use for late-stage prostate cancer. December 10, 2012. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm331492.htm. Accessed: December 17, 2012.
Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27. 367(13):1187-97. [QxMD MEDLINE Link].
Shore ND, Chowdhury S, Villers A, Klotz L, Siemens DR, Phung D, et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol. 2016 Feb. 17 (2):153-63. [QxMD MEDLINE Link].
Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2018 Jun 28. 378 (26):2465-2474. [QxMD MEDLINE Link].
FDA approves enzalutamide for metastatic castration-sensitive prostate cancer. U.S. Food & Drug Administration. Available at https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enzalutamide-metastatic-castration-sensitive-prostate-cancer. December 17, 2019; Accessed: January 22, 2022.
de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP,et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet. 2010 Oct 2. 376(9747):1147-54. [QxMD MEDLINE Link].
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med. 2018 Feb 8. [QxMD MEDLINE Link]. [Full Text].
Fizazi K, et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med. 2019 Mar 28. 380 (13):1235-1246. [QxMD MEDLINE Link]. [Full Text].
Abida W, Campbell D, Patnaik A, Sautois B, Shapiro J, Vogelzang NJ, et al. Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): updated analyses. Ann Oncol 2019;30 (suppl 5):abst 846PD. [Full Text].
de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 Apr 28. [QxMD MEDLINE Link].
Targeted Therapy Slows Progression of Advanced Prostate Cancer [ESMO 2019 Press Release]. European Society for Medical Oncology. Available at https://www.esmo.org/Press-Office/Press-Releases/ESMO-Congress-prostate-cancer-olaparib-Profound-Hussain. September 30, 2019; Accessed: December 19, 2019.
Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 Sep 20. [QxMD MEDLINE Link].
Brooks M. FDA Grants Expanded Indication for Enzalutamide (Xtandi). Medscape Medical News. Available at http://www.medscape.com/viewarticle/831548. Accessed: September 14, 2014.
Rusthoven CG, Jones BL, Flaig TW, Crawford ED, Koshy M, Sher DJ, et al. Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer. J Clin Oncol. 2016 Jun 20. [QxMD MEDLINE Link].
Roqué I Figuls M, Martinez-Zapata MJ, Scott-Brown M, Alonso-Coello P. Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev. 2011 Jul 6. CD003347. [QxMD MEDLINE Link].
US Food and Drug Administration. FDA approves new drug for advanced prostate cancer [press release]. May 15, 2013. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm352363.htm. Accessed: July 1, 2013.
Hoskin P, Sartor O, O'Sullivan JM, Johannessen DC, Helle SI, Logue J, et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet Oncol. 2014 Nov. 15 (12):1397-406. [QxMD MEDLINE Link].
Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TL, Ke C, et al. Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol. 2012 Sep 10. 30(26):3271-6. [QxMD MEDLINE Link]. [Full Text].
FDA Drug Safety Communication: Update to Ongoing Safety Review of GnRH Agonists and Notification to Manufacturers of GnRH Agonists to Add New Safety Information to Labeling Regarding Increased Risk of Diabetes and Certain Cardiovascular Diseases. U.S. Food & Drug Administration. Available at http://www.fda.gov/Drugs/DrugSafety/ucm229986.htm. October 20, 2010; Accessed: February 16, 2018.
Gillessen S, Templeton A, Marra G, Kuo YF, Valtorta E, Shahinian VB. Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer. J Natl Cancer Inst. 2010 Dec 1. 102(23):1760-70. [QxMD MEDLINE Link]. [Full Text].
Morgans AK, Hancock ML, Barnette KG, Steiner MS, Morton RA, Smith MR. Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2012 Mar. 187(3):889-93. [QxMD MEDLINE Link].
Boonen S, Reginster JY, Kaufman JM, Lippuner K, et al. Fracture risk and zoledronic acid therapy in men with osteoporosis. N Engl J Med. 2012 Nov. 367(18):1714-23. [QxMD MEDLINE Link].
Smith MR, Egerdie B, Hernández Toriz N, Feldman R, et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009 Aug 20. 361(8):745-55. [QxMD MEDLINE Link]. [Full Text].
Fizazi K, Carducci M, Smith M, Damião R, Brown J, etc. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet. 2011 Mar 5. 377(9768):813-22. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Skolarus TA, Wolf AM, Erb NL, Brooks DD, Rivers BM, Underwood W 3rd, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin. 2014 Jul-Aug. 64 (4):225-49. [QxMD MEDLINE Link]. [Full Text].
Abramowitz MC, Li T, Buyyounouski MK, Ross E, Uzzo RG, Pollack A, et al. The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer. 2008 Jan 1. 112(1):55-60. [QxMD MEDLINE Link].
Dickinson L, Ahmed HU, Allen C, Barentsz JO, Carey B,et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting. Eur Urol. 2011 Apr. 59(4):477-94. [QxMD MEDLINE Link].
Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. JAMA. 2009 Jan 7. 301(1):52-62. [QxMD MEDLINE Link]. [Full Text].
Lippman SM, Klein EA, Goodman PJ, Lucia MS, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2009 Jan 7. 301(1):39-51. [QxMD MEDLINE Link].
Liu Y, Hu F, Li D, Wang F, Zhu L, Chen W, et al. Does physical activity reduce the risk of prostate cancer? A systematic review and meta-analysis. Eur Urol. 2011 Nov. 60(5):1029-44. [QxMD MEDLINE Link].
Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003 Jul 17. 349(3):215-24. [QxMD MEDLINE Link].
Andriole GL, Bostwick DG, Brawley OW, Gomella LG, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010 Apr 1. 362(13):1192-202. [QxMD MEDLINE Link].
Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003 Jul 17. 349 (3):215-24. [QxMD MEDLINE Link].
Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA Jr, Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res (Phila). 2008 Aug. 1 (3):174-81. [QxMD MEDLINE Link].
Andriole GL, Bostwick D, Brawley OW, Gomella L, Marberger M, Montorsi F, et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol. 2011 Jan. 185 (1):126-31. [QxMD MEDLINE Link].
Kramer BS, Hagerty KL, Justman S, Somerfield MR, et al. Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline. J Clin Oncol. 2009 Mar 20. 27(9):1502-16. [QxMD MEDLINE Link]. [Full Text].
FDA Drug Safety Communication: 5-alpha reductase inhibitors (5-ARIs) may increase the risk of a more serious form of prostate cancer. U.S. Food & Drug Administration. Available at http://www.fda.gov/Drugs/DrugSafety/ucm258314.htm. June 9, 2011; Accessed: February 16, 2018.
Fleshner NE, Lucia MS, Egerdie B, Aaron L, Eure G, Nandy I, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet. 2012 Mar 24. 379(9821):1103-11. [QxMD MEDLINE Link].
[Guideline] Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, et al. Early detection of prostate cancer: AUA guideline. American Urological Association. Available at https://www.auanet.org/guidelines/early-detection-of-prostate-cancer-(2013-reviewed-and-validity-confirmed-2015). 2015; Accessed: February 16, 2018.
[Guideline] Prostate Cancer: Screening. U.S. Preventive Services Task Force. Available at http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/prostate-cancer-screening?ds=1&s=prostate. May 8, 2018; Accessed: September 30, 2022.
[Guideline] Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P. Screening for Prostate Cancer: A Guidance Statement From the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med. 2013 Apr 9. [QxMD MEDLINE Link].
Parker C, Gillessen S, Heidenreich A, Horwich A, ESMO Guidelines Committee. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015 Sep. 26 Suppl 5:v69-77. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Mottet N, Bellmunt J, Briers E, et al. EAU-ESTRO-SIOG GUIDELINES ON PROSTATE CANCER. European Association of Urology. Available at http://uroweb.org/wp-content/uploads/EAU-Guidelines-Prostate-Cancer-2016.pdf. March 2016; Accessed: September 14, 2020.
[Guideline] Chen RC, Rumble RB, Loblaw DA, Finelli A, Ehdaie B, Cooperberg MR, et al. Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2016 Jun 20. 34 (18):2182-90. [QxMD MEDLINE Link]. [Full Text].
DeCastro GJ, Jayram G, Razmaria A, Shalhav A, Zagaja GP. Functional outcomes in African-Americans after robot-assisted radical prostatectomy. J Endourol. 2012 Aug. 26(8):1013-9. [QxMD MEDLINE Link].
Smith MR, Saad F, et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet. 2012 Jan 7. 379(9810):39-46. [QxMD MEDLINE Link].
Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol. 2008 Aug. 54(2):344-52. [QxMD MEDLINE Link].
Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA. 2010 Dec 1. 304(21):2373-80. [QxMD MEDLINE Link]. [Full Text].
[Guideline] Basch E, Loblaw DA, Oliver TK, Carducci M, Chen RC, Frame JN, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014 Oct 20. 32 (30):3436-48. [QxMD MEDLINE Link].
[Guideline] Trabulsi EJ, Rumble RB, Jadvar H, et al. Optimum Imaging Strategies for Advanced Prostate Cancer: ASCO Guideline. J Clin Oncol. 2020 Jan 15. JCO1902757. [QxMD MEDLINE Link].
Lapi F, Azoulay L, Niazi MT, Yin H, Benayoun S, Suissa S. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer. JAMA. 2013 Jul 17. 310(3):289-96. [QxMD MEDLINE Link].
[Guideline] Bankhead C. Prostate Ca Guidelines Center on Primary Care. MedPage Today. Jun 11 2014. [Full Text].
Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999 Dec 9. 341(24):1781-8. [QxMD MEDLINE Link].
Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009 Jun 11. 360(24):2516-27. [QxMD MEDLINE Link].
Bria E, Cuppone F, Giannarelli D, Milella M, et al. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials. Cancer. 2009 Aug 1. 115(15):3446-56. [QxMD MEDLINE Link].
Fosså SD, Wiklund F, Klepp O, Angelsen A, Solberg A, Damber JE, et al. Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7. Eur Urol. 2016 Oct. 70 (4):684-691. [QxMD MEDLINE Link]. [Full Text].
Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, et al. Germline mutations in HOXB13 and prostate-cancer risk. N Engl J Med. 2012 Jan 12. 366(2):141-9. [QxMD MEDLINE Link].
Fowler JE Jr, Sanders J, Bigler SA, Rigdon J, Kilambi NK, Land SA. Percent free prostate specific antigen and cancer detection in black and white men with total prostate specific antigen 2.5 to 9.9 ng./ml. J Urol. 2000 May. 163(5):1467-70. [QxMD MEDLINE Link].
Scavonetto F, Yeoh TY, Umbreit EC, et al. Association between neuraxial analgesia, cancer progression, and mortality after radical prostatectomy: a large, retrospective matched cohort study. Br J Anaesth. 2013 Dec 16. [QxMD MEDLINE Link].
Markert EK, Mizuno H, Vazquez A, Levine AJ. Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci U S A. 2011 Dec 27. 108(52):21276-81. [QxMD MEDLINE Link]. [Full Text].
Ilic D, Djulbegovic M, Jung JH, Hwang EC, Zhou Q, Cleves A, et al. Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis. BMJ. 2018 Sep 5. 362:k3519. [QxMD MEDLINE Link]. [Full Text].
American Urological Association. AUA Disputes Panel’s Recommendations on Prostate Cancer Screening. Available at https://www.prnewswire.com/news-releases/aua-disputes-panels-recommendations-on-prostate-cancer-screening-152349275.html. May 21, 2012; Accessed: August 6, 2019.
Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009 Mar 26. 360(13):1310-9. [QxMD MEDLINE Link]. [Full Text].
Schröder FH, Hugosson J, Roobol MJ, Tammela TL, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009 Mar 26. 360(13):1320-8. [QxMD MEDLINE Link].
Page EC, Bancroft EK, Brook MN, et al. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. Eur Urol. 2019 Sep 16. [QxMD MEDLINE Link]. [Full Text].
Ahmed HU, Bosaily AE-S, Brown LC, et al; PROMIS study group. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 19 January 2017. [Full Text].
Cornelis F, Rigou G, Le Bras Y, et al. Real-time contrast-enhanced transrectal US-guided prostate biopsy: diagnostic accuracy in men with previously negative biopsy results and positive MR imaging findings. Radiology. 2013 Oct. 269(1):159-66. [QxMD MEDLINE Link].
Stewart GD, Van Neste L, Delvenne P, Delrée P, Delga A, McNeill SA, et al. Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC study. J Urol. 2013 Mar. 189 (3):1110-6. [QxMD MEDLINE Link].
National Cancer Institute. Prostate Cancer Screening (PDQ®). Available at http://www.cancer.gov/cancertopics/pdq/screening/prostate/HealthProfessional/allpages. April 22, 2020; Accessed: May 22, 2020.
Rosario DJ, Lane JA, Metcalfe C, Donovan JL, Doble A, et al. Short term outcomes of prostate biopsy in men tested for cancer by prostate specific antigen: prospective evaluation within ProtecT study. BMJ. 2012 Jan 9. 344:d7894. [QxMD MEDLINE Link]. [Full Text].
Eiber M, Rauscher I, Souvatzoglou M, Maurer T, Schwaiger M, Holzapfel K, et al. Prospective head-to-head comparison of ¹¹C-choline-PET/MR and ¹¹C-choline-PET/CT for restaging of biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2017 Dec. 44 (13):2179-2188. [QxMD MEDLINE Link].
[Guideline] Expert Panel on Urologic Imaging:., Coakley FV, Oto A, Alexander LF, Allen BC, Davis BJ, et al. ACR Appropriateness Criteria^® Prostate Cancer-Pretreatment Detection, Surveillance, and Staging. J Am Coll Radiol. 2017 May. 14 (5S):S245-S257. [QxMD MEDLINE Link].
Ellis RJ, Kaminsky DA, Zhou EH, Fu P, Chen WD, Brelin A, et al. Ten-year outcomes: the clinical utility of single photon emission computed tomography/computed tomography capromab pendetide (Prostascint) in a cohort diagnosed with localized prostate cancer. Int J Radiat Oncol Biol Phys. 2011 Sep 1. 81(1):29-34. [QxMD MEDLINE Link].
Haese A, Epstein JI, Huland H, Partin AW. Validation of a biopsy-based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinoma. Cancer. 2002 Sep 1. 95(5):1016-21. [QxMD MEDLINE Link].
Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, et al. Fifteen-Year Survival Outcomes Following Primary Androgen-Deprivation Therapy for Localized Prostate Cancer. JAMA Intern Med. 2014 Jul 14. [QxMD MEDLINE Link].
Cantiello F, Russo GI, Kaufmann S, Cacciamani G, Crocerossa F, Ferro M, et al. Role of multiparametric magnetic resonance imaging for patients under active surveillance for prostate cancer: a systematic review with diagnostic meta-analysis. Prostate Cancer Prostatic Dis. 2019 May. 22 (2):206-220. [QxMD MEDLINE Link].
Sheets NC, Goldin GH, Meyer AM, Wu Y, Chang Y, et al. Intensity-modulated radiation therapy, proton therapy, or conformal radiation therapy and morbidity and disease control in localized prostate cancer. JAMA. 2012 Apr 18. 307(15):1611-20. [QxMD MEDLINE Link].
Briganti A, Wiegel T, Joniau S, Cozzarini C, Bianchi M, et al. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur Urol. 2012 Sep. 62(3):472-87. [QxMD MEDLINE Link].
Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol. 2011 Apr. 59(4):572-83. [QxMD MEDLINE Link].
de Vrij J, Willemsen RA, Lindholm L, Hoeben RC, et al. Adenovirus-derived vectors for prostate cancer gene therapy. Hum Gene Ther. 2010 Jul. 21(7):795-805. [QxMD MEDLINE Link].
Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [¹⁷⁷Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018 Jun. 19 (6):825-833. [QxMD MEDLINE Link].
McBean R, O'Kane B, Parsons R, Wong D. Lu177-PSMA therapy for men with advanced prostate cancer: Initial 18 months experience at a single Australian tertiary institution. J Med Imaging Radiat Oncol. 2019 Apr 25. [QxMD MEDLINE Link].
Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-7.
[Guideline] Cookson MS, Roth BJ, Dahm P, et al. Castration-Resistant Prostate Cancer: AUA Guideline. American Urological Association. Available at https://www.auanet.org/guidelines/castration-resistant-prostate-cancer-(2013-amended-2015). Published 2013; Amended 2018; Accessed: January 20, 2022.
Kishan AU, Cook RR, Ciezki JP, ... King CR. Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. JAMA. 2018 Mar 6. 319 (9):896-905. [QxMD MEDLINE Link].

Media Gallery

Prostate cancer. This diagram depicts the relevant anatomy of the male pelvis and genitourinary tract.
Prostate cancer. Histologic scoring system showing the 2 most common patterns seen on the biopsy specimen, termed the Gleason score.
Prostate cancer. The standard approach for grading prostate cancer depends on a Gleason score, which is based on pathologic evaluation of a prostatectomy specimen and is commonly estimated from prostate biopsy tissue. Prostate cancer patterns are assigned a number from 1-5; the score is created by adding the most common pattern and the highest-grade patterns. Courtesy of Wikimedia Commons.
Prostate cancer. Adenocarcinoma around a small nerve (center). Courtesy of Thomas M. Wheeler, MD.
Prostate cancer. Small focus of adenocarcinoma on needle biopsy on right side of slide (normal glands on left side). Courtesy of Thomas M. Wheeler, MD.
Prostate cancer. Immunohistochemical stains showing normal basal cells (brown) in a benign gland with no basal cells in malignant glands (on right side with no brown staining). Malignant glands show increased expression of racemase (red cytoplasmic stain). Courtesy of Thomas M. Wheeler, MD.
Prostate cancer. Micrograph of high-grade prostatic intraepithelial neoplasia
Prostate cancer. Diagram illustrates the progression of prostate cancer and associated treatment options.

of 8

Table 1. Comparison of Gleason grade and modern Grade Groups.

Gleason Grade	Grade Groups
3+3	1
3+4	2
4+3	3
4+4, 3+5, 5+3	4
4+5, 5+4, 5+5	5

Table 2. Prostate cancer screening recommendations from 4 major organizations

Organization	Screening Tools	Ages to Screen	Repeat Testing Interval	Indication for Prostate Biopsy
NCCN (2018)	PSA and DRE	45-75 >75 (only in very healthy men)	PSA* < 1 ng/mL, 2-4 years PSA* 1-3 ng/mL, 1-2 years	PSA > 3 ng/mL or Suspicious DRE
AUA (2018)	PSA	-Not indicated in men < 40 -Not recommended in men 40-54** -After shared decision making for men 55-69 -Not recommended for men >70 or men with life expectancy < 10-15 yrs	2 or more years	Consider if PSA >3, but with additional consideration of factors affecting PSA***
EAU (2016)	PSA	Risk adapted model after shared decision making for men with a life-expectancy >10-15 years -Men >50 -Men >45 with a family history -African American men >45 -Men with PSA >1 ng/mL at age 40 -Men with PSA >2 ng/mL at age 60	Risk adapted: -Every 2 years for men with PSA >1 ng/mL at age 40 or PSA >2 ng/mL at age 60 - Every 8 years for those not at risk	-PSA should be addressed continuously - Consider the addition of novel risk assays
ACS (2019)	PSA +/-DRE	Risk adapted model after shared decision making -Men >50, life expectancy > 10 years -Men >45 at high risk -Men >40 at very high risk¥	PSA* < 2.5 ng/mL, 2 yrs PSA* >2.5 ng/mL, 1 yr	Not discussed
assumes normal DRE Screening should be individualized for men aged 40-54 and those at higher risk, such as African-American men, men with a family history of metastatic or lethal adenocarcinoma (including prostate, breast, ovarian, and pancreatic cancers), multiple affected first-degree relatives of affected generations, and family members with cancer detected at younger ages. **A second confirmatory PSA should be obtained prior to biopsy ǂ African-American men or men with a first-degree relative with prostate cancer diagnosed at < 65 years of age ¥ More than one first-degree relative with prostate cancer at an early age

Table 3. International Society of Urological Pathology (ISUP) grading system

ISUP Grade	Gleason Score	Definition
1	2-6	Only individual discrete well-formed glands
2	3+4=7	Predominantly well-formed glands with lesser component of poorly formed/fused/cribriform glands
3	4+3=7	Predominantly poorly formed/fused/cribriform glands with lesser component of well-formed glands
4	4+4=8	Only poorly formed/fused/cribriform glands
	3+5=8	Predominantly well-formed glands and lesser component lacking glands (or with necrosis)
	5+3=8	Predominantly lacking glands (or with necrosis) and lesser component of well-formed glands
5	59–10	Lacking gland formation (or with necrosis) with or without poorly formed/fused

Back to List

Author

Chad R Tracy, MD Assistant Professor, Department of Urology, University of Iowa, Roy J and Lucille A Carver College of Medicine

Chad R Tracy, MD is a member of the following medical societies: American Medical Association, American Urological Association, Endourological Society

Disclosure: Nothing to disclose.

Coauthor(s)

Nathan A Brooks, MD Resident Physician, Department of Urology, University of Iowa Hospitals and Clinics

Nathan A Brooks, MD is a member of the following medical societies: American Urological Association

Disclosure: Nothing to disclose.

Mohammed Said, MD Fellow in Minimally Invasive Surgery and Endourology, Department of Urology, University of Iowa, Roy J and Lucille A Carver College of Medicine

Disclosure: Nothing to disclose.

Chief Editor

Edward David Kim, MD, FACS Professor of Urology, Department of Urology, University of Tennessee Graduate School of Medicine; Consulting Staff, University of Tennessee Medical Center

Edward David Kim, MD, FACS is a member of the following medical societies: American Society for Reproductive Medicine, American Urological Association, Sexual Medicine Society of North America, Society for Male Reproduction and Urology, Society for the Study of Male Reproduction, Tennessee Medical Association

Disclosure: Serve(d) as a speaker or a member of a speakers bureau for: Endo, Antares.

Additional Contributors

Tracey L Krupski, MD, MPH Assistant Professor, Department of Urology, University of Virginia School of Medicine

Tracey L Krupski, MD, MPH is a member of the following medical societies: American Medical Association, American Urological Association, American Society of Clinical Oncology, Society of Women in Urology

Disclosure: Nothing to disclose.

Bagi RP Jana, MD, MBA, MHA, FACP Professor of Cancer Medicine, MD Anderson Cancer Center; Professor of Medicine, University of Texas Medical Branch at Galveston

Bagi RP Jana, MD, MBA, MHA, FACP is a member of the following medical societies: American Cancer Society, American Medical Association, American Society of Clinical Oncology, SWOG

Disclosure: Nothing to disclose.

Gerald W Chodak, MD  Editor, www.ProstateVideos.com; Medscape Urology, Experts and Viewpoints--Controversies in Urology; Director of Medical Content, Answers Media, LLC; Author, Winning the Battle Against Prostate Cancer

Gerald W Chodak, MD is a member of the following medical societies: American Urological Association

Disclosure: Nothing to disclose.

Acknowledgements

Isamettin Andrew Aral, MD, MSc Attending Physician, Nassau Radiologic Group (Long Island Radiation Therapy); Clinical Assistant Professor of Radiation Oncology, State University of New York Downstate College of Medicine

Isamettin Andrew Aral, MD, MSc, is a member of the following medical societies: American College of Radiology, American Medical Association, and American Society for Therapeutic Radiology and Oncology